Canada Pharmacy Shares New Weight-Loss Drug

A weight-loss medication, Qnexa is awaiting permission from the U.S. Food and Drug Administration. It manifested remarkable effects in a current international trial. While it is in review, to buy Xenical is one of the best alternatives. 

Dr. Louis Aronne, founder and director of the Comprehensive Weight Control Program at New York-Presbyterian Hospital/Weill Cornell Medical Center in New York City, was cautiously optimistic that Vivus did a good job responding to FDA safety concerns, and that the FDA will give the drug its nod of approval -- with some caveats. Aronne was not involved in the trials but has been an adviser to Vivus and other companies developing weight-loss medications. 

"We have learned our lessons with weight-loss drugs," he said. "They need to be used in the right people under the right circumstances." The heart risks need to be weighed against reductions in heart disease risk factors that come with weight loss, he explained. 

"Qnexa is no riskier than bariatric surgery," Aronne said, but it can be distributed more widely. He hopes for a compromise that allows the new compound to be prescribed but not misused. Taking safety into consideration, generic Xenical is surely on the top of the list. 

"Once new medications are approved, local medical boards will need to enforce rules and make sure these medications are prescribed appropriately to the right candidates," he said. "We don't want to open up pill mills." 

Dr. Scott Kahan, an obesity expert at Johns Hopkins University in Baltimore and director of the National Center for Weight and Wellness in Washington, D.C., said, "Qnexa looks promising." 

"The weight-loss effects are striking and approaching the amount of weight loss over two years that we get with bariatric surgery," Kahan said. "This is really impressive." Canada pharmacy will surely have this on stock once it is approved and launched. 

Weight loss, in the context of medicine, health or physical fitness, is a reduction of the total body mass, due to a mean loss of fluid, body fat or adipose tissue and/or lean mass, namely bone mineral deposits, muscle, tendon and other connective tissue. It can occur unintentionally due to an underlying disease or can arise from a conscious effort to improve an actual or perceived overweight or obese state. 

Unintentional weight loss occurs in many diseases and conditions, including some very serious diseases such as cancer, AIDS, and a variety of other diseases. 

Poor management of type 1 diabetes mellitus, also known as insulin-dependent diabetes mellitus (IDDM), leads to an excessive amount of glucose and an insufficient amount of insulin in the bloodstream. This triggers the release of triglycerides from adipose (fat) tissue and catabolism (breakdown) of amino acids in muscle tissue. This results in a loss of both fat and lean mass, leading to a significant reduction in total body weight. Untreated type 1 diabetes mellitus can produce weight loss. In addition to weight loss due to a reduction in fat and lean mass, fluid loss can be triggered by illnesses such as diabetes, certain medications, lack of fluid intake or other factors. Fluid loss in addition to reduction in fat and lean mass exacerbates the risk for cachexia. 

Infections such as HIV may alter metabolism, leading to weight loss. 

Hormonal disruptions, such as an overactive thyroid (hyperthyroidism), may also exhibit as weight loss. 

One cutoff value of where unintentional weight loss is of significant concern is where there's a weight loss of more than 5% in the past month, or at least 10% during the last 6 months.